Covid-19 Vaccine: Serum Institute Begins Manufacturing First Batch Of Novavax

Clinical trials of Novavax are being conducted and are in an advanced stage of completion in India.

Covavax Vaccine

Serum Institute of India (SII) CEO Adar Poonawalla on Friday said that SII has this week begun manufacturing the first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc.

Serum Institute of India (SII) CEO Adar Poonawalla in a tweet said the Novavax vaccine has “great potential to protect our future generations below the age of 18. Trials are ongoing.” US-based Novavax Inc has a vaccine manufacturing agreement with Serum Institute of India, which also manufactures the Covishield vaccine currently administered in the country.


Novavax’s vaccine showed a 90.4% overall efficacy in Phase-3 clinical trials. It is as effective as as two of the frontline vaccines being used in the US and European countries –Pfizer-BioNTech and Moderna, which had efficacy rates of 91.3% and 90% in Phase 3 trials, respectively.

Clinical trials of Novavax are being conducted and are in an advanced stage of completion in India.

In August last year, the American vaccine maker, Novavax Inc, had announced a licence agreement with SII Pune for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.

“What we’re learning from data available in the public domain that this vaccine is very safe and highly effective,” said Dr VK Paul, Member-Health, Niti Aayog said earlier this month.

Facebook Comments